Allo-HCT outcomes for blastic plasmacytoid dendritic cell neoplasm

Murthy HS, Zhang M-J, Chen K, et al. Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A CIBMTR Analysis. Blood Advances. 2023; (doi: 10.1182/bloodadvances.2023011308).

A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis found that allogeneic hematopoietic cell transplantation (allo-HCT) resulted in durable remissions and long-term survival in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The study included 164 patients with BPDCN who received allo-HCT between 2007 and 2018. After a median follow-up of 49 months for survivors, the 5-year overall survival (OS) rate was 51.2% and disease-free survival (DFS) was 44.4%. The rates of relapse and non-relapse mortality were 32.2% and 23.3%, respectively. The most common cause of death was disease relapse. Factors predictive of inferior OS were age ≥60 years and remission status at time of allo-HCT (CR2/PIF/Relapse vs CR1). Age ≥60 was also predictive of higher NRM, while remission status at time of transplantation was also predictive of inferior OS. Myeloablative conditioning with total body irradiation was associated with improved DFS and lower risk of relapse for patients with BPDCN.

Read More

Tags: AlloHCT, CIBMTR, Allogeneic, allogeneic HCT, long term, remission

Theme picker